The rationale behind combining these two classes of drugs has been that both anti-apoptotic Bcl-2-family proteins and BCR signaling are usually overexpressed or overactivated, respectively, in B-CLL. Here, BCR is linked to B-cell chronic lymphocytic leukemia.